{{Drugbox
| verifiedrevid = 459128585
| IUPAC_name =  7-methoxy-1-(2-morpholin-4-ylethyl)-''N''-[(1''R'',3''S'',4''S'')-2,2,4-trimethyl-3-bicyclo[2.2.1]heptanyl]indole-3-carboxamide
| image = MN-25 structure.svg
| width =

<!--Clinical data-->
| pregnancy_category =  
| legal_CA = Schedule II
| legal_status =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 501926-82-5
| CAS_number2 =  501927-29-3
| index_label =
| index2_label = 2-methyl derivative
| ATC_prefix =  
| ATC_suffix =  
| UNII = 8WXU5YRE25
| UNII_Ref = {{fdacite|correct|FDA}}
| PubChem = 71308243
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} 
| DrugBank =  
|  ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 26286811
| ChEMBL = 3234671
| synonyms = ''N''-[(''S'')-Fenchyl]-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide
<!--Chemical data-->
| C=26|H=37|N=3|O=3
| molecular_weight =  439.59 g/mol
| smiles = COC1=C(N(CCN2CCOCC2)C=C3C(N[C@H]4[C@@]5(C)CC[C@H](C5)C4(C)C)=O)C3=CC=C1
|  StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H37N3O3/c1-25(2)18-8-9-26(3,16-18)24(25)27-23(30)20-17-29(11-10-28-12-14-32-15-13-28)22-19(20)6-5-7-21(22)31-4/h5-7,17-18,24H,8-16H2,1-4H3,(H,27,30)/t18-,24-,26+/m1/s1
|  StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VQGDMQICNRCQEH-UFKXBGGNSA-N
  }}

'''MN-25''' ('''UR-12''') is a drug invented by [[Bristol-Myers Squibb]],<ref>[http://www.wipo.int/patentscope/search/docservicepdf_pct/090063618003495e?download CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS IN TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES. WO 2001/58869]</ref> that acts as a reasonably selective [[agonist]] of peripheral [[cannabinoid receptor]]s.<ref>[http://www.arkat-usa.org/get-file/31700/ Rulin Zhao, ''et al.'' Improved procedure for the preparation of 7-methoxy-2-methyl-1-(2-morpholinoethyl)-1H-indole-3-carboxylic acid, key intermediate in the synthesis of novel 3-amidoindole and indolopyridone cannabinoid ligands. ARKIVOC 2010 (vi):89-95.]</ref> It has moderate affinity for [[Cannabinoid receptor type 2|CB<sub>2</sub> receptors]] with a [[Dissociation constant|''K''<sub>i</sub>]] of 11&nbsp;nM, but 22x lower affinity for the psychoactive [[Cannabinoid receptor type 1|CB<sub>1</sub> receptors]] with a ''K''<sub>i</sub> of 245&nbsp;nM. The indole 2-methyl derivative has the ratio of affinities reversed however, with a ''K''<sub>i</sub> of 8&nbsp;nM at CB<sub>1</sub> and 29&nbsp;nM at CB<sub>2</sub>,<ref>{{Cite journal |author= Hynes, J.|doi= 10.1016/S0960-894X(02)00466-3 |title= C-3 Amido-Indole cannabinoid receptor modulators | journal = Bioorganic & Medicinal Chemistry Letters |volume= 12 |issue= 17 |pages= 2399–402 |year= 2002 |pmid=  12161142 |display-authors=etal}}
</ref><ref>{{cite journal |doi= 10.1021/jm020329q |title= Rational Design and Synthesis of an Orally Active Indolopyridone as a Novel Conformationally Constrained Cannabinoid Ligand Possessing Antiinflammatory Properties |year= 2003 |author= Wrobleski, Stephen T.|journal= Journal of Medicinal Chemistry |volume= 46 |issue= 11 |pages= 2110–6 |pmid= 12747783|display-authors=etal}}</ref> which contrasts with the usual trend of 2-methyl derivatives having increased selectivity for CB<sub>2</sub> (cf. [[JWH-018]] vs [[JWH-007]], [[JWH-081]] vs [[JWH-098]]).<ref>{{Cite journal | last1 = Huffman | first1 = J. W. | last2 = Padgett | first2 = L. W. | doi = 10.2174/0929867054020864 | title = Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes | journal = Current Medicinal Chemistry | volume = 12 | issue = 12 | pages = 1395–1411 | year = 2005 | pmid =  15974991| pmc = }}</ref><ref>{{Cite journal | last1 = Manera | first1 = C. | last2 = Tuccinardi | first2 = T. | last3 = Martinelli | first3 = A. | doi = 10.2174/138955708783955935 | title = Indoles and Related Compounds as Cannabinoid Ligands | journal = Mini Reviews in Medicinal Chemistry | volume = 8 | issue = 4 | pages = 370–387 | year = 2008 | pmid =  18473928| pmc = }}</ref>

Chemically, it is closely related to another indole-3-carboxamide synthetic cannabinoid, [[Org 28611]], but with a different cycloalkyl substitution on the carboxamide, and the cyclohexylmethyl group replaced by morpholinylethyl, as in [[JWH-200]] or [[A-796,260]]. Early compounds such as these have subsequently led to the development of a large number of related indole-3-carboxamide cannabinoid ligands.<ref>{{Cite journal |author= Adam, J. M.|title= Design, synthesis, and structure–activity relationships of indole-3-carboxamides as novel water soluble cannabinoid CB1 receptor agonists |doi= 10.1039/c0md00022a |journal= [[MedChemComm]]|publisher= [[Royal Society of Chemistry]]|volume= 1 |pages= 54 |year= 2010 |display-authors=etal}}</ref><ref name="p20634067">{{cite journal  |vauthors=Kiyoi T, etal |title=Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists |journal=Bioorganic & Medicinal Chemistry Letters |volume=20 |issue=16 |pages=4918–21 |date=August 2010 |pmid=20634067 |doi=10.1016/j.bmcl.2010.06.067 |url=}}</ref><ref name="p21074434">{{cite journal  |vauthors=Moir EM, etal |title=Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists |journal=Bioorganic & Medicinal Chemistry Letters |volume=20 |issue=24 |pages=7327–30 |date=December 2010 |pmid=21074434 |doi=10.1016/j.bmcl.2010.10.061 }}</ref><ref>{{Cite journal |author= Blaazer, A. R.|doi= 10.1016/j.ejmech.2011.08.021 |title= Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure–activity relationships, physicochemical properties and biological activity |journal= European Journal of Medicinal Chemistry |volume= 46 |issue= 10 |pages= 5086–5098 |year= 2011 |pmid= 21885167 |display-authors=etal}}
</ref>

==See also==
* [[A-834,735]]
* [[AB-001]]
* [[AM-1221]]
* [[JTE 7-31]]
* [[JWH-203]]
* [[MDA-19]]
* [[SR-144,528]]
* [[UR-144]]

==References==
{{reflist}}

==Further reading==
# John Hynes., ''et al.'' C3 AMIDO-INDOLE CANNABINOID RECEPTOR MODULATORS. Bioorganic and Medical Chemistry Letters. Volume 12 issue 17, 2 September 2002 pages 2399-2402
# Frost, J. M., ''et al.'' (2010). "Indol -3-ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB2 Cannabinoid Receptor Activity". Journal of Medicinal Chemistry 53 (1): 295. {{doi|10.1021/}} jm901214q. {{PMID|19921781}}
# Chin CL, ''et al.'' (January 2008). "Differential effects of cannabinoid receptor agonists on regional brain activity
using pharmacological MRI". British Journal of Pharmacology 153 (2): 367–79. {{doi|10.1038/}} sj.bjp .0707506. {{PMC|2219521}}. {{PMID|17965748}}

{{Cannabinoids}}

[[Category:Aminoalkylindoles]]
[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indoles]]
[[Category:Indolecarboxamides]]